Cite
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor.
MLA
Wierda, William G., et al. “Venetoclax for Chronic Lymphocytic Leukaemia Patients Who Progress after More than One B‐cell Receptor Pathway Inhibitor.” British Journal of Haematology, vol. 185, no. 5, June 2019, pp. 961–66. EBSCOhost, https://doi.org/10.1111/bjh.15666.
APA
Wierda, W. G., Byrd, J. C., Davids, M. S., Furman, R. R., Cheson, B. D., Barr, P. M., Eradat, H., Heffner, L., Zhou, L., Verdugo, M., Potluri, J., & Choi, M. (2019). Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor. British Journal of Haematology, 185(5), 961–966. https://doi.org/10.1111/bjh.15666
Chicago
Wierda, William G., John C. Byrd, Matthew S. Davids, Richard R. Furman, Bruce D. Cheson, Paul M. Barr, Herbert Eradat, et al. 2019. “Venetoclax for Chronic Lymphocytic Leukaemia Patients Who Progress after More than One B‐cell Receptor Pathway Inhibitor.” British Journal of Haematology 185 (5): 961–66. doi:10.1111/bjh.15666.